BioCentury | Feb 23, 2021
Product Development

Meniere disease pipeline: Data Byte

Otonomy’s negative Phase III readout calls into question the utility of targeting the glucocorticoid receptor to treat Meniere disease.  There are no approved drugs to treat the disorder, which is caused by the buildup of...
BioCentury | Feb 5, 2021

GameStop survivors target biotech shares, but ‘BioWar’ unlikely despite bolus of short-friendly stocks

Day traders have long used Reddit forums, chat rooms and Twitter to talk up biotech stocks, but it’s unlikely they could organize in sufficient numbers to move a stock on the scale of GameStop....
BioCentury | Jan 15, 2021

A maturing mid-cap sector could keep funds flowing into biotech

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...
BioCentury | Nov 7, 2020

Galapagos gains new antifibrotic mechanism through OncoArendi deal

Galapagos’ latest move to expand its early fibrosis pipeline, via a deal with Polish biotech OncoArendi, gives the company access to a new fibrosis-blocking immune mechanism.  Through the exclusive collaboration and licensing agreement, Galapagos N.V....
BioCentury | Aug 26, 2020

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
BioCentury | Jul 30, 2020
Product Development

Sanofi, AZ pave the way for new RSV mAb with long-lasting protection data

Sanofi and AstraZeneca are on track to deliver an RSV-preventing mAb that would be more accessible and possibly more effective than Synagis in infants. In a New England Journal of Medicine paper published on Wednesday,...
BioCentury | Jul 10, 2020

With record fund flows, biotech a top sector for investors heading into 3Q20

Investors expect the massive inflows to biotech to continue over the next quarter as the sector is viewed as a top defensive pick in a struggling global economy that is unlikely to improve until the...
BioCentury | Jun 12, 2020

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...
BioCentury | May 12, 2020

NBI hits all-time high as biotech stocks surge

The NASDAQ Biotechnology Index rose 168.42, or 4%, to 4,201.88 on Monday, reaching an all-time high on the back of substantial inflows into the sector. Twenty-eight companies gained double-digit percentage points as the NBI breached...
BioCentury | May 8, 2020

Follow-on market poised for comeback, at least temporarily

Pandemic-driven market volatility has stymied follow-on activity the past two months, but stabilizing markets and big inflows are opening a window of opportunity, at least in the near term. The unfolding consequences of COVID-19 could...
Items per page:
1 - 10 of 806